AECOM Share Price Target ‘$108.56’, now 21.2% Upside Potential

DirectorsTalk Interviews

AECOM with ticker code (ACM) have now 9 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $116.00 and $100.00 calculating the mean target share price we have $108.56. (at the time of writing). Given that the stocks previous close was at $89.57 and the analysts are correct then we can expect a percentage increase in value of 21.2%. Also worth taking note is the 50 day moving average now sits at $93.99 and the 200 day MA is $88.35. The total market capitalization for the company now stands at 12.27B. The stock price is currently at: $90.14 USD

The potential market cap would be $14,871,991,066 based on the market consensus.

The company has a dividend yield of 0.03%. Other points of data to note are a P/E ratio of 103.61, revenue per share of $111.89 and a 4.65% return on assets.

AECOM is a global provider of professional infrastructure consulting services for governments, businesses, and organizations across the world. The Company operates through three segments: Americas, International, and AECOM Capital (ACAP). The Americas segment provides planning, consulting, architectural and engineering design, and construction and program management services to commercial and government clients in the United States, Canada, and Latin America in end markets, such as transportation, water, government, facilities, environmental, and energy. The International segment offers planning, consulting, architectural and engineering design services and program management to commercial and government clients in Europe, the Middle East, Africa and the Asia-Pacific regions in end markets, such as transportation, water, government, facilities, environmental, and energy. The ACAP segment invests primarily in and develops real estate projects.

Share on:

Latest Company News

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products.

PPHE Hotel Group refinances Park Plaza Victoria London

PPHE Hotel Group has agreed a new £88 million refinancing facility for Park Plaza Victoria London, replacing an existing loan due to mature in early 2026.

Greggs Plc appoints Richard Smothers as Non-Executive Director

Greggs plc has announced the appointment of Richard Smothers as an independent Non-Executive Director, effective from 1 February 2026.

Hollywood Bowl Group reports FY2025 results with revenue growth

Hollywood Bowl Group has published its audited results for the year ended 30 September 2025, reporting revenue growth of 8.8% to £250.7m and a fourth consecutive year of record revenue and adjusted EBITDA.

Centrica Plc agrees sale of Spirit Energy assets to Serica

Centrica has announced the sale of Spirit Energy’s remaining interests in the Cygnus gas field and other producing assets in the Southern North Sea to Serica Energy.

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.

    Search

    Search